What is HC Wainwright’s Estimate for TNYA FY2026 Earnings?

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Equities researchers at HC Wainwright boosted their FY2026 EPS estimates for shares of Tenaya Therapeutics in a report issued on Thursday, August 6th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($0.37) per share for the year, up from their prior estimate of ($0.51). The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for Tenaya Therapeutics’ FY2027 earnings at ($0.35) EPS and FY2028 earnings at ($0.42) EPS.

A number of other equities research analysts have also commented on TNYA. Wall Street Zen lowered Tenaya Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 6th. Weiss Ratings upgraded shares of Tenaya Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $4.00.

Tenaya Therapeutics Stock Performance

Shares of TNYA opened at $0.74 on Monday. The stock has a 50-day moving average of $0.77 and a two-hundred day moving average of $0.76. The stock has a market cap of $160.02 million, a P/E ratio of -1.39 and a beta of 2.83. Tenaya Therapeutics has a one year low of $0.53 and a one year high of $2.35.

Tenaya Therapeutics (NASDAQ:TNYA) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.13). The business had revenue of $1.11 million for the quarter, compared to analyst estimates of $10.00 million.

Institutional Trading of Tenaya Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of TNYA. Renaissance Technologies LLC grew its stake in shares of Tenaya Therapeutics by 100.6% during the 1st quarter. Renaissance Technologies LLC now owns 3,713,761 shares of the company’s stock worth $2,571,000 after purchasing an additional 1,862,894 shares during the period. Empery Asset Management LP acquired a new position in shares of Tenaya Therapeutics in the 4th quarter valued at $3,852,000. GSA Capital Partners LLP boosted its holdings in Tenaya Therapeutics by 220.2% during the fourth quarter. GSA Capital Partners LLP now owns 1,478,612 shares of the company’s stock worth $1,052,000 after buying an additional 1,016,808 shares in the last quarter. Integrity Wealth Solutions LLC purchased a new stake in Tenaya Therapeutics during the first quarter worth $27,000. Finally, Castleview Partners LLC acquired a new stake in Tenaya Therapeutics during the first quarter valued at $106,000. 90.54% of the stock is owned by institutional investors and hedge funds.

About Tenaya Therapeutics

Tenaya Therapeutics is a clinical?stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno?associated virus (AAV) platform, the company aims to deliver durable, one?time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.